Your session is about to expire
← Back to Search
BR-I + Venetoclax for Mantle Cell Lymphoma
Study Summary
This trial will test the safety of adding Venetoclax to the standard BR-I cancer treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have previously been treated with a medication called venetoclax or a similar medication that targets BCL-2.You have a history of brain or spinal cord disease caused by cancer. However, if you have received successful treatment and there is no sign of the disease or need for steroids, you may still be eligible.You have received a stem cell transplant from your own body within the past three months.You have received a stem cell transplant from another person within the past year.You have experienced allergic reactions or bad side effects from the study drugs before.You have another type of cancer that needs to be treated right now.You cannot participate if you currently have an active graft-versus-host disease.You have been treated with a medication called ibrutinib or acalabrutinib (or a similar type of medication) before, and it showed some positive effect on your condition. You did not get worse within 6 months of starting the treatment.
- Group 1: BR-I in combination with VEN
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has there been any other research conducted on the combination of bendamustine, rituximab, and ibrutinib?
"Coined in 1993 by the National Institutes of Health Clinical Center located at 9000 Rockville Pike, BR-I (bendamustine, rituximab and ibrutinib) has since been trialled 991 times. At present there are 718 active trials being conducted across Montvale, New york."
Are any individuals currently eligible to participate in this research trial?
"Per clinicaltrials.gov, this trial is not presently accepting any participants; it was initially posted on September 20th 2017 and the listing's last update occurred on February 3rd 2022. Although this investigation has closed its recruitment window, there are an additional 2442 other studies that may be of interest to patients seeking treatment options currently."
What pathologies is BR-I (bendamustine, rituximab, ibrutinib) usually indicated for?
"BR-I (bendamustine, rituximab, ibrutinib) is predominantly prescribed to those suffering from diffuse large b-cell lymphoma. It has also been known to bring relief for hodgkin disease, b-cell lymphomas and polyangium patients."
How many locations are hosting this research endeavor?
"Currently, this medical trial is being held at 7 different sites. These include Montvale and New york in Commack, as well as 5 other locations. If you choose to join the study, it might be wise to select a clinic near your residence so that travel costs are kept minimal."
How many participants are currently being admitted to this trial?
"Unfortunately, no new applicants are being accepted for this trial at the moment; it was posted on 9/20/2017 and has not been updated since 2/3/2022. If you're looking for other clinical trials related to lymphoma, there is an abundance of active studies with 1724 recruiting patients in that area alone and 718 enrolling participants into BR-I (bendamustine, rituximab, ibrutinib) research."
Share this study with friends
Copy Link
Messenger